TriangleNCT02860286 · OUTCOME
Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): Tmax
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Hour
- Interval / dispersion
- Inter-Quartile Range
- Time frame
- Cycle 1 Day 15: pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and12 post-dose.
Groups in this outcome
Part 1 (Pharmacokinetics)
Assessment of pharmacokinetic (PK) and safety profile of single (Cycle 1 day 1) and repeated doses (Cycle 1 day 2 onwards) of 800 mg tazemetostat administered as 400 mg tablets in subjects with relapsed or refractory malignant mesothelioma regardless of BRCA1 associated protein 1 (BAP1) status.
| Group | Source count |
|---|---|
| Part 1 (Pharmacokinetics) | 13 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1 (Pharmacokinetics) | 1.1 | Not reported | 1 | 4 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1
- upper Limit
- 4
- value
- 1.1
- denoms
- counts
- group Id
- OG000
- value
- 13
- units
- Participants
- dispersion Type
- Inter-Quartile Range
- groups
- description
- Assessment of pharmacokinetic (PK) and safety profile of single (Cycle 1 day 1) and repeated doses (Cycle 1 day 2 onwards) of 800 mg tazemetostat administered as 400 mg tablets in subjects with relapsed or refractory malignant mesothelioma regardless of BRCA1 associated protein 1 (BAP1) status.
- id
- OG000
- title
- Part 1 (Pharmacokinetics)
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- Cycle 1 Day 15: pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and12 post-dose.
- title
- Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): Tmax
- type
- PRIMARY
- unit Of Measure
- Hour
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice